

Donald C Vinh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7826080/publications.pdf>

Version: 2024-02-01

141
papers

12,842
citations

66234

42
h-index

26548

107
g-index

149
all docs

149
docs citations

149
times ranked

20317
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	5.6	35
2	miR-181c regulates MCL1 and cell survival in GATA2 deficient cells. <i>Journal of Leukocyte Biology</i> , 2022, 111, 805-816.	1.5	3
3	Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 64-73.	0.6	11
4	A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 159-164.	7.0	41
5	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	13.7	216
6	Lack of evidence for intergenerational inheritance of immune resistance to infections. <i>Nature Immunology</i> , 2022, 23, 203-207.	7.0	17
7	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. <i>Journal of Proteome Research</i> , 2022, 21, 975-992.	1.8	27
8	BCG vaccination provides protection against IAV but not SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110502.	2.9	51
9	Studying severe long COVID to understand post-infectious disorders beyond COVID-19. <i>Nature Medicine</i> , 2022, 28, 879-882.	15.2	72
10	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. <i>CMAJ Open</i> , 2022, 10, E379-E389.	1.1	3
11	Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?. <i>Skin Therapy Letter</i> , 2022, 27, 1-5.	0.3	0
12	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
13	Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*. <i>Critical Care Medicine</i> , 2022, 50, 1306-1317.	0.4	10
14	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, .	4.7	14
15	Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	21
16	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	59
17	Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study. <i>Journal of Clinical Immunology</i> , 2021, 41, 66-75.	2.0	3
18	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	4.6	586

#	ARTICLE	IF	CITATIONS
19	Treatment of Secondary Immunodeficiencies. , 2021, , .		0
20	Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study. Journal of Clinical Immunology, 2021, 41, 458-469.	2.0	4
21	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	2.2	41
22	The Biobanque qu'Ã©bÃ©coise de la COVID-19 (BQC19)â€™A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE, 2021, 16, e0245031.	1.1	30
23	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Annals of Oncology, 2021, 32, 787-800.	0.6	240
24	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-Î². Journal of Clinical Immunology, 2021, 41, 1425-1442.	2.0	39
25	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15
26	From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemicâ€™Associated Pernio. Journal of Investigative Dermatology, 2021, 141, 2791-2796.	0.3	21
27	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
28	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	5.6	267
29	Infections in secondary immunodeficiency patients treated with Privigen^{Â®} or Hizentra^{Â®}: a retrospective US administrative claims study in patients with hematological malignancies. Leukemia and Lymphoma, 2021, 62, 3463-3473.	0.6	5
30	A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3293-3307.e6.	2.0	7
31	ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency. Current Opinion in Immunology, 2021, 72, 21-26.	2.4	12
32	Fecal host biomarkers predicting severity of Clostridioides difficile infection. JCI Insight, 2021, 6, .	2.3	4
33	Late-Onset Combined Immunodeficiency with Refractory CMV Disease due to ICOSL Deficiency. Journal of Clinical Immunology, 2021, , 1.	2.0	1
34	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
35	Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110521.	0.6	12
36	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	2.8	32

#	ARTICLE	IF	CITATIONS
37	Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome. <i>Lancet, The</i> , 2021, 398, 2101.	6.3	0
38	Novel CARD9 mutation in a patient with chronic invasive dermatophyte infection (tinea profunda). <i>Journal of Cutaneous Pathology</i> , 2020, 47, 166-170.	0.7	24
39	High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. <i>European Journal of Cancer</i> , 2020, 139, 181-187.	1.3	65
40	Feasibility of Subcutaneous IgPro20 Administration via Manual Push at High Flow Rates in Patients with Primary Immunodeficiency: Findings of the HILO Study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB217.	1.5	0
41	Safety Profile of High IgPro20 Infusion Parameters in Patients with Primary Immunodeficiency (PID): Results from The Forced Upward Titration HILO Study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB32.	1.5	0
42	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope™ Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	1.7	20
43	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
44	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
45	Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 479-491.e5.	1.5	52
46	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
47	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. <i>Cell</i> , 2020, 181, 1194-1199.	13.5	185
48	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
49	The HILO Study: High Volumes and Flow Rates of Subcutaneous IgPro20 Pump-assisted Infusions in Patients with Primary Immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB216.	1.5	1
50	CARD9 Deficiency. , 2020, , 96-117.		0
51	Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia. , 2020, , .		0
52	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	1.3	30
53	Disseminated Pruritic Macules in a Solid Organ Transplant Recipient. <i>Clinical Infectious Diseases</i> , 2019, 69, 897-899.	2.9	0
54	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies™ Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.1	5

#	ARTICLE	IF	CITATIONS
55	CD109 Restrains Activation of Cutaneous IL-17-Producing $\hat{I}3\hat{I}$ T Cells by Commensal Microbiota. Cell Reports, 2019, 29, 391-405.e5.	2.9	21
56	Severe disseminated <i>Nocardia</i> infection associated with ustekinumab treatment for psoriasis. British Journal of Dermatology, 2019, 181, 194-195.	1.4	3
57	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology, 2019, 46, 751-754.	1.0	22
58	Leukotriene B ₄ –type I interferon axis regulates macrophage-mediated disease tolerance to influenza infection. Nature Microbiology, 2019, 4, 1389-1400.	5.9	31
59	Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases. Journal of Clinical Immunology, 2019, 39, 216-224.	2.0	21
60	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. Emerging Infectious Diseases, 2019, 25, 838-840.	2.0	7
61	The molecular immunology of human susceptibility to fungal diseases: lessons from single gene defects of immunity. Expert Review of Clinical Immunology, 2019, 15, 461-486.	1.3	6
62	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. Journal of Cutaneous Medicine and Surgery, 2019, 23, 50-74.	0.6	87
63	GATA2 Deficiency Due to de Novo Complete Monoallelic Deletion in an Adolescent With Myelodysplasia. Journal of Pediatric Hematology/Oncology, 2018, 40, e225-e228.	0.3	4
64	The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia and Lymphoma, 2018, 59, 2159-2174.	0.6	6
65	Novel bi-allelic splice mutations in <i>CARD9</i> causing adult-onset <i>Candida</i> endophthalmitis. Mycoses, 2018, 61, 61-65.	1.8	18
66	CARD9 Deficiency. , 2018, , 1-22.		0
67	Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opinion on Drug Delivery, 2018, 15, 1199-1209.	2.4	8
68	Loss of human ICOSL results in combined immunodeficiency. Journal of Experimental Medicine, 2018, 215, 3151-3164.	4.2	40
69	Back from the brink of obscurity. ELife, 2018, 7, .	2.8	1
70	GM-CSF therapy in human caspase recruitment domain–containing protein 9 deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 1334-1338.e5.	1.5	24
71	Pre-filled Syringes For Immunoglobulin Therapy: A Pragmatic Review Of Clinical Experience From Other Disease Settings. Journal of Allergy and Clinical Immunology, 2018, 141, AB266.	1.5	0
72	Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 1688-1692.e10.	1.5	14

#	ARTICLE	IF	CITATIONS
73	SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. <i>Nature</i> , 2017, 544, 493-497.	13.7	188
74	Case of Reversible Complete Heart Block. <i>American Journal of Medicine</i> , 2017, 130, e335-e336.	0.6	1
75	Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. <i>Clinical Transplantation</i> , 2017, 31, e13058.	0.8	28
76	Inborn errors of immunity underlying fungal diseases in otherwise healthy individuals. <i>Current Opinion in Microbiology</i> , 2017, 40, 46-57.	2.3	101
77	RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection. <i>PLoS Pathogens</i> , 2017, 13, e1006326.	2.1	60
78	CARD9 Deficiency. , 2017, , 1-22.		0
79	Abstract 2447: The mutational landscape of chemo-refractory Burkitt lymphoma. , 2017, , .		0
80	Clinical and Molecular Epidemiology of <i>Histoplasma capsulatum</i> in Quebec, Canada. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
81	A Cluster of Three Cases of <i>Hantavirus</i> Pulmonary Syndrome among Canadian Military Personnel. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-4.	0.7	5
82	A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. <i>Current Oncology</i> , 2016, 23, 42-51.	0.9	28
83	Primary immunodeficiency associated with chromosomal aberration – an ESID survey. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 110.	1.2	23
84	Chronic mucocutaneous candidiasis presenting as <i>Candida</i> endophthalmitis. <i>Canadian Journal of Ophthalmology</i> , 2016, 51, e55-e58.	0.4	4
85	Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1178-1188.e7.	1.5	92
86	Treatment of Endocarditis. , 2016, , 181-280.		1
87	Prophylaxis of Endocarditis. , 2016, , 67-90.		0
88	Risk Factors for Progression of CMV Viremia to CMV Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S296-S297.	2.0	1
89	Invasive <i>Saccharomyces cerevisiae</i> in a liver transplant patient: case report and review of infection in transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 435-441.	0.7	21
90	The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps. <i>PLoS Pathogens</i> , 2015, 11, e1005187.	2.1	167

#	ARTICLE	IF	CITATIONS
91	Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1069-1100.	1.3	11
92	CARD9 Deficiency and Spontaneous Central Nervous System Candidiasis: Complete Clinical Remission With GM-CSF Therapy. <i>Clinical Infectious Diseases</i> , 2014, 59, 81-84.	2.9	153
93	Crohn's as an immune deficiency: from apparent paradox to evolving paradigm. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 17-30.	1.3	20
94	Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1624-1634.e17.	1.5	222
95	Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?. <i>Case Reports in Immunology</i> , 2013, 2013, 1-5.	0.2	6
96	Bobo-Newton Syndrome: An Unwanted Gift from Man's Best Friend. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 209-214.	0.7	22
97	Acquired Omenn-Like Syndrome, a Novel Posttransplant Autoaggression Syndrome Reversed by Rapamycin. <i>Vaccine Journal</i> , 2012, 19, 109-112.	3.2	1
98	MCL-1 and Mir-181c in GATA2 Mutation Associated Monoclonal and Familial Myelodysplastic Syndrome. <i>Blood</i> , 2012, 120, 3807-3807.	0.6	0
99	Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. <i>Blood</i> , 2011, 118, 2653-2655.	0.6	572
100	Insights into human antifungal immunity from primary immunodeficiencies. <i>Lancet Infectious Diseases</i> , 2011, 11, 780-792.	4.6	72
101	Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. <i>Haematologica</i> , 2011, 96, 1221-1225.	1.7	97
102	Interleukin-12 Receptor α 1 Deficiency Predisposing to Disseminated Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2011, 52, e99-e102.	2.9	87
103	Coccidioidal Meningitis. <i>Medicine (United States)</i> , 2011, 90, 87.	0.4	10
104	Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. <i>Blood</i> , 2010, 115, 1519-1529.	0.6	299
105	NADPH Oxidase Limits Innate Immune Responses in the Lungs in Mice. <i>PLoS ONE</i> , 2010, 5, e9631.	1.1	161
106	Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21, e122-e150.	0.7	56
107	<i>Neosartorya udagawae</i> (<i>Aspergillus udagawae</i>), an Emerging Agent of Aspergillosis: How Different Is It from <i>Aspergillus fumigatus</i> ?. <i>Journal of Clinical Microbiology</i> , 2010, 48, 220-228.	1.8	68
108	Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1389-1390.	1.5	91

#	ARTICLE	IF	CITATIONS
109	Famciclovir: a focus on efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 643-658.	1.0	17
110	Refractory Disseminated Coccidioidomycosis and Mycobacteriosis in Interferon- β Receptor 1 Deficiency. <i>Clinical Infectious Diseases</i> , 2009, 49, e62-e65.	2.9	109
111	Chronic Invasive Aspergillosis caused by <i>Aspergillus viridinutans</i> . <i>Emerging Infectious Diseases</i> , 2009, 15, 1292-1294.	2.0	54
112	Invasive Aspergillosis Due to <i>Neosartorya udagawae</i> . <i>Clinical Infectious Diseases</i> , 2009, 49, 102-111.	2.9	103
113	Linezolid: a review of safety and tolerability. <i>Journal of Infection</i> , 2009, 59, S59-S74.	1.7	170
114	Mucormycosis in chronic granulomatous disease: Association with iatrogenic immunosuppression. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1411-1413.	1.5	42
115	Yeast Infections – Human Genetics on the Rise. <i>New England Journal of Medicine</i> , 2009, 361, 1798-1801.	13.9	33
116	Hantavirus Pulmonary Syndrome: A Concise Clinical Review. <i>Southern Medical Journal</i> , 2009, 102, 620-625.	0.3	11
117	The man who got too close to his cows. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 419-420.	0.8	16
118	An Elderly Woman with a Diffuse Annular Eruption. <i>Clinical Infectious Diseases</i> , 2008, 46, 1581-1581.	2.9	0
119	2007 International Congress on Respiratory Viruses. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, S49-S51.	1.1	1
120	First Report of Isolation and Characterization of <i>Aurantimonas altamirensis</i> from Clinical Samples. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2435-2437.	1.8	21
121	Evaluation of a Commercial Direct Fluorescent-Antibody Assay for Human Metapneumovirus in Respiratory Specimens. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1840-1841.	1.8	25
122	<i>Legionella jordanis</i> Lower Respiratory Tract Infection: Case Report and Review. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2321-2323.	1.8	11
123	Severe skin and soft tissue infections and associated critical illness. <i>Current Infectious Disease Reports</i> , 2007, 9, 415-421.	1.3	14
124	Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2271-2286.	0.9	12
125	Rapidly progressive soft tissue infections – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 66-67.	4.6	2
126	Native-valve bacterial endocarditis caused by <i>Lactococcus garvieae</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 91-94.	0.8	53

#	ARTICLE	IF	CITATIONS
127	<i>Vibrio vulnificus</i> Septicemia after Handling <i>Tilapia</i> Species Fish: A Canadian Case Report and Review. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 129-132.	0.7	20
128	Breast implant infection with Mycobacterium fortuitum group: Report of case and review. Journal of Infection, 2006, 52, e63-e67.	1.7	46
129	Severe skin and soft tissue infections and associated critical illness. Current Infectious Disease Reports, 2006, 8, 375-383.	1.3	7
130	Clinical Applications of Induced Sputum. Chest, 2006, 130, 1626-1627.	0.4	2
131	Not So Pretty in Pink: Staphylococcus cohnii Masquerading as Methicillin-Resistant Staphylococcus aureus on Chromogenic Media. Journal of Clinical Microbiology, 2006, 44, 4623-4624.	1.8	5
132	Treatment of Native Valve Endocarditis: General Principles and Therapy for Specific Organisms. , 2006, , 121-183.		2
133	Candida dubliniensis bloodstream infection: a fatal case in a lung transplant recipient. Transplant Infectious Disease, 2005, 7, 146-149.	0.7	18
134	Crohn's Disease and M. paratuberculosis: Where's the Beef?. Inflammatory Bowel Diseases, 2005, 11, 1025-1027.	0.9	3
135	Device-Related Infections: A Review. Journal of Long-Term Effects of Medical Implants, 2005, 15, 467-488.	0.2	108
136	Strains and toxins of Clostridium. Cmaj, 2005, 172, 312-313.	0.9	4
137	Infection in breast implants. Lancet Infectious Diseases, The, 2005, 5, 462-463.	4.6	9
138	Rapidly progressive soft tissue infections. Lancet Infectious Diseases, The, 2005, 5, 501-513.	4.6	97
139	Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infectious Diseases, The, 2003, 3, 148-155.	4.6	710
140	Real-World Serologic Responses to Extended-Interval and Heterologous COVID-19 mRNA Vaccination in Frail Elderly - Interim Report from a Prospective Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	1
141	Macrophage Classical Activation. , 0, , 301-323.		0